Biocon Ltd, a leading biopharmaceutical firm, plans to invest $150 million in capital expenditures over the next two years, targeting expansion in both its biologics and generics segments. Of the total investment, $100 million is allocated to its biologics division, while $50 million will support the generics business.
Malaysia to See Major Biologics Investment
According to Kedar Upadhye, CFO of Biocon Biologics, a substantial portion of the biologics capex will be directed toward capacity expansion in Malaysia. He noted that capex in biologics will likely moderate after two years, signaling a shift to more stable investments post-expansion. Siddharth Mittal, Managing Director and CEO of Biocon, said, “Post this, we expect only minimal maintenance capex”.
Strong Financial Performance in Q4
Biocon reported a robust 153% surge in net profit to ₹344 crore for Q4, with total consolidated revenue growing 12% year-on-year to ₹4,454 crore. Group Chairperson Kiran Mazumdar-Shaw attributed the strong performance to “growth in generics, steady biosimilars momentum, and continued demand for research services.”
New Launches Strengthen US and UK Presence
During the quarter, Biocon launched key products including:
- Lenalidomide and dasatinib (oncology drugs) in the US
- Liraglutide (anti-diabetes) in the UK
These launches mark Biocon’s deepening presence in advanced markets.
Future Growth Anchored in Peptides and Biosimilars
Biocon is sharpening its focus on peptide-based therapies, especially GLP-1 receptor agonists, which it views as a critical growth driver. The company also continues to scale its biosimilar portfolio, with four biosimilars generating $200 million each in sales during FY25. According to Matthew Erick, Chief Commercial Officer – Advanced Markets, Biocon Biologics, the US launch of oncology drug bevacizumab is on track for H1 FY26, alongside anticipated approval for insulin aspart.
Biosimilar Momentum Builds in Global Markets
Biocon recently launched Yesintek (biosimilar ustekinumab)—one of the first biosimilars to Stelara—in the US. Analysts see this, along with aflibercept biosimilar positioning, as key enablers of continued US market penetration.
Expanding Manufacturing and Strengthening Finances
Biocon subsidiary Syngene expanded its biologics manufacturing footprint through a US facility acquisition during the quarter. The company also plans to raise ₹4,500 crore via QIP and private placement. Proceeds will primarily be used to meet financial commitments related to its biologics business investments.
Positioned to Capitalize on Global Insulin Demand
“With rising global insulin demand and our large-scale manufacturing capacity, Biocon is well-positioned to seize this growth opportunity,” said Kiran Mazumdar-Shaw. As reported by pharmajobspost.in, the company’s diversified strategy and strong product pipeline reflect its ambition to lead the future of affordable and accessible healthcare globally.
